[Senate Report 116-328]
[From the U.S. Government Publishing Office]


                                                        Calendar No. 634

116th Congress  }                                              {  Report
                                  SENATE                          
2d Session      }                                              {  116-328
_______________________________________________________________________

 
                                                       



      PREVENTING OPIOID AND DRUG IMPAIRMENT IN TRANSPORTATION ACT

                               __________

                              R E P O R T

                                 of the

           COMMITTEE ON COMMERCE, SCIENCE, AND TRANSPORTATION

                                   on

                                S. 2979





               December 15, 2020.--Ordered to be printed
               
               
                            ______

             U.S. GOVERNMENT PUBLISHING OFFICE 
19-010                 WASHINGTON : 2020 
                
               
               
               
       SENATE COMMITTEE ON COMMERCE, SCIENCE, AND TRANSPORTATION
                     one hundred sixteenth congress
                             second session

                 ROGER F. WICKER, Mississippi, Chairman
JOHN THUNE, South Dakota             MARIA CANTWELL, Washington
ROY BLUNT, Missouri                  AMY KLOBUCHAR, Minnesota
TED CRUZ, Texas                      RICHARD BLUMENTHAL, Connecticut
DEB FISCHER, Nebraska                BRIAN SCHATZ, Hawaii
JERRY MORAN, Kansas                  EDWARD J. MARKEY, Massachusetts
DAN SULLIVAN, Alaska                 TOM UDALL, New Mexico
CORY GARDNER, Colorado               GARY C. PETERS, Michigan
MARSHA BLACKBURN, Tennessee          TAMMY BALDWIN, Wisconsin
SHELLEY MOORE CAPITO, West Virginia  TAMMY DUCKWORTH, Illinois
MIKE LEE, Utah                       JON TESTER, Montana
RON JOHNSON, Wisconsin               KYRSTEN SINEMA, Arizona
TODD C. YOUNG, Indiana               JACKY ROSEN, Nevada
RICK SCOTT, Florida
                       John Keast, Staff Director
               David Strickland, Minority Staff Director
               
               

                                                       Calendar No. 634
                                                       
116th Congress  }                                              {  Report
                                 SENATE
 2d Session     }                                              {  116-328

======================================================================



 
      PREVENTING OPIOID AND DRUG IMPAIRMENT IN TRANSPORTATION ACT
                                _______
                                

               December 15, 2020.--Ordered to be printed

                                _______
                                

       Mr. Wicker, from the Committee on Commerce, Science, and 
                Transportation, submitted the following

                              R E P O R T

                         [To accompany S. 2979]

    [Including and cost estimate of the Congressional Budget Office]

    The Committee on Commerce, Science, and Transportation, to 
which was referred the bill (S. 2979) to improve drug testing 
for transportation-related activities, having considered the 
same, reports favorably thereon with an amendment (in the 
nature of a substitute) and recommends that the bill (as 
amended) do pass.

                          PURPOSE OF THE BILL

    The purpose of S. 2979 is to further improve drug and 
alcohol testing requirements for employees in safety-sensitive 
transportation positions and initiate research that would 
assist with preventing drug-impaired driving on our Nation's 
roads.

                          BACKGROUND AND NEEDS

    In recent years, Congress has undertaken efforts to prevent 
opioid and other drug abuse and overdose through efforts such 
as the SUPPORT for Patients and Communities Act.\1\ S. 2979 
would further those efforts by better tracking drug use of 
employees in safety-sensitive transportation positions, 
creating improvements in drug and alcohol testing processes to 
better utilize U.S. Department of Transportation (DOT) 
resources, and initiating research to assist in better 
identifying and preventing drug-impaired driving.
---------------------------------------------------------------------------
    \1\Public Law 115-271.
---------------------------------------------------------------------------
    Drug and alcohol testing is critical for the safety of our 
Nation's roadways. DOT oversees the administration and 
improvement of drug and alcohol testing for employees in 
safety-sensitive transportation positions and works to reduce 
impaired driving for individuals on our Nation's highways. 
DOT's Office of Drug and Alcohol Policy and Compliance (ODAPC) 
and its modal administrations currently require drug and 
alcohol testing for more than 12 million transportation workers 
in the aviation, trucking, railroad, mass transit, pipeline, 
maritime, and other transportation industries.\2\ In addition, 
the National Highway Traffic Safety Administration (NHTSA) is 
responsible for reducing deaths and injuries from motor vehicle 
crashes and works with States and law enforcement to reduce 
impaired driving, both for alcohol and drugs, through grant 
programs, driver behavior standards, and education campaigns.
---------------------------------------------------------------------------
    \2\U.S. Department of Transportation, Office of Drug and Alcohol 
Policy and Compliance, ``Employees: What Are the Drug & Alcohol Testing 
Rules and Where Do I Find Them?,'' updated Jul. 1, 2020 (https://
www.transportation.gov/odapc/employee#drugalcohol) (accessed Sep. 14, 
2020). Note that the 12 million transportation workers includes 
employees subject to regulations of the U.S. Coast Guard, which is part 
of the U.S. Department of Homeland Security.
---------------------------------------------------------------------------
    Drug-impaired driving has been of increasing concern in 
recent years, particularly given the surge in opioid abuse and 
changes in State drug laws. Drug-impaired driving negatively 
impacts drivers' coordination, judgement, and reaction 
times.\3\ In 2016 alone, there were more than 42,000 opioid 
overdose deaths,\4\ and drivers are increasingly testing 
positive for marijuana.\5\ Recent post-crash test data show 
significant increases in the number of operators or drivers 
impaired by opioids and involved in crashes.\6\ In addition, 
DOT lab-reported drug testing data for safety-sensitive 
transportation workers from 2011 to 2015 showed increases in 
positive drug tests for opiates and amphetamines.\7\
---------------------------------------------------------------------------
    \3\U.S. Department of Transportation, National Highway Traffic 
Safety Administration, ``Drug-Impaired Driving'' (https://
www.nhtsa.gov/risky-driving/drug-impaired-driving#32451) (accessed Sep. 
14, 2020).
    \4\National Institutes of Health, National Institute on Drug Abuse, 
``Nearly Half of Opioid-related Overdose Deaths Involve Fentanyl,'' May 
1, 2018 (https://www.drugabuse.gov/news-events/news-releases/2018/05/
nearly-half-opioid-related-overdose-deaths-involve-fentanyl) (accessed 
Sep. 14, 2020).
    \5\Jim Hedlund, Governors Highway Safety Association, Drug-Impaired 
Driving: Marijuana and Opioids Raise Critical Issues for States, p. 12, 
May 2018 (https://www.ghsa.org/resources/DUID18) (accessed Sep. 14, 
2020); U.S. Department of Transportation, National Highway Traffic 
Safety Administration, ``Drug-Impaired Driving'' (https://
www.nhtsa.gov/risky-driving/drug-
impaired-driving#32451) (accessed Sep. 14, 2020).
    \6\Jim Hedlund, Governors' Highway Safety Association, Drug-
Impaired Driving: Marijuana and Opioids Raise Critical Issues for 
States, May 2018 (https://www.ghsa.org/resources/DUID18) (accessed Sep. 
14, 2020).
    \7\U.S. Department of Transportation, Office of the Secretary of 
Transportation, Office of Drug and Alcohol Policy and Compliance, ``DOT 
Program Update: Federal Drug Testing Advisory Board,'' May 20, 2016, 
slide 16 (https://www.samhsa.gov/sites/default/files/meeting/documents/
kelly-dot-dtab-may-2016.pdf) (accessed Sep. 14, 2020).
---------------------------------------------------------------------------
    For transportation employees in safety-sensitive positions, 
DOT follows the Department of Health and Human Services (HHS) 
Mandatory Guidelines for Federal Workplace Drug Testing 
Programs (HHS Mandatory Guidelines) to determine the drug 
testing panel for which drug testing is required.\8\ DOT, 
however, has some discretion in how it regulates the modal 
administration drug testing programs. ODAPC is responsible for 
advising DOT on such issues and publishing drug and alcohol 
testing regulations for the transportation industry.
---------------------------------------------------------------------------
    \8\Omnibus Transportation Employee Testing Act of 1991 (Pub. L. 
102-143).
---------------------------------------------------------------------------
    On January 23, 2017, HHS revised its HHS Mandatory 
Guidelines to include synthetic opioids--specifically 
oxycodone, oxymorphone, hydrocodone, and hydromorphone--on the 
panel of controlled substances for which Federal agencies can 
test.\9\ Following revision of the HHS Mandatory Guidelines, on 
November 13, 2017, DOT published a final rule adding these 
synthetic opioids to its drug testing panel used for 
transportation workers subject to DOT drug and alcohol testing 
regulations.\10\ Notably, fentanyl, a synthetic opioid 
responsible for approximately 19,000 deaths in 2016--46 percent 
of all opioid overdose deaths that year--was not included on 
the panel.\11\ Section 8105 of the SUPPORT for Patients and 
Communities Act\12\ required HHS within 180 days of enactment 
to determine whether a revision of the HHS Mandatory Guidelines 
to expand the opiate category on the list of authorized 
substance testing to include fentanyl, based on the reliability 
and cost-effectiveness on available testing.
---------------------------------------------------------------------------
    \9\U.S. Department of Health and Human Services, Substance Abuse 
and Mental Health Services Administration, ``Mandatory Guidelines for 
Federal Workplace Drug Testing Programs,'' 82 Fed. Reg. 7920 (Jan. 23, 
2017) (https://www.govinfo.gov/content/pkg/FR-2017-01-23/pdf/2017-
00979.pdf) (accessed Sep. 14, 2020).
    \10\U.S. Department of Transportation, Office of the Secretary, 
``Procedures for Transportation Workplace Drug and Alcohol Testing 
Programs: Addition of Certain Schedule II Drugs to the Department of 
Transportation's Drug-Testing Panel and Certain Minor Amendments,'' 82 
Fed. Reg. 52229 (Nov. 13, 2017) (https://www.govinfo.gov/content/pkg/
FR-2017-11-13/pdf/2017-24397.pdf) (accessed Sep. 14, 2020).
    \11\National Institutes of Health, National Institute on Drug 
Abuse, ``Nearly Half of Opioid-related Overdose Deaths Involve 
Fentanyl,'' May 1, 2018 (https://www.drugabuse.gov/news-events/news-
releases/2018/05/nearly-half-opioid-related-overdose-deaths-involve-
fentanyl) (accessed Sep. 14, 2020).
    \12\Public Law 115-271.
---------------------------------------------------------------------------
    As a general matter, urine, oral fluid, and hair testing 
are available methods of testing for concentrations of 
controlled substances. However, under the HHS Mandatory 
Guidelines, urine testing currently is the only form of drug 
testing that may be used to test transportation employees 
subject to DOT drug and alcohol testing regulations.
    The Fixing America's Surface Transportation (FAST) Act of 
2015\13\ required HHS to issue, within 1 year after enactment, 
guidelines for hair testing as a method of detecting use of a 
controlled substance.\14\ Section 8106 of the SUPPORT for 
Patients and Communities Act\15\ required HHS within 60 days of 
enactment to provide Congress with the current status and 
expected timeline of testing guidelines. These guidelines had 
not yet been released upon introduction of S. 2979.
---------------------------------------------------------------------------
    \13\Public Law 114-94.
    \14\FAST Act, section 5402 (codified at 49 U.S.C. Sec. 31306 note).
    \15\Public Law 115-271.
---------------------------------------------------------------------------
    Finally, with increased opioid abuse and the legalization 
of recreational marijuana use in some States, concerns related 
to drug-impaired driving on our Nation's roads have been 
increasingly prevalent. In addition, roadside technology to 
detect drug presence and impairment is still under development. 
Despite the fact that it is illegal to drive impaired, whether 
by alcohol or drugs, NHTSA's 2013-2014 National Roadside Survey 
found that the number of drivers testing positive for marijuana 
increased between 2007 and 2014.\16\ The survey further found 
that 20 percent of nighttime weekend drivers tested positive 
for drugs.\17\ Additionally, in 2016, NHTSA conducted a 
comprehensive case-control study to estimate the crash risk of 
alcohol-positive, drug-positive, and drug- and alcohol-positive 
drivers. The study confirmed previous research indicating that 
alcohol is a greater contributor to crash risk than drugs, but 
hypothesized that the consumption of drugs, alone or with 
alcohol, may be associated with crash severity.\18\ In 2018, 
NHTSA announced the If You Feel Different, You Drive Different 
education campaign to inform drivers of the dangers of drug-
impaired driving.
---------------------------------------------------------------------------
    \16\U.S. Department of Transportation, National Highway Traffic 
Safety Administration, ``Drug-Impaired Driving'' (https://
www.nhtsa.gov/risky-driving/drug-impaired-driving#32451) (accessed Sep. 
14, 2020).
    \17\Amy Berning et al., U.S. Department of Transportation, National 
Highway Traffic Safety Administration, Traffic Safety Facts: Results of 
the 2013-2014 National Roadside Survey of Alcohol and Drug Use by 
Drivers, DOT HS 812 118, Feb. 2015 (https://www.nhtsa.gov/sites/
nhtsa.dot.gov/files/812118-roadside_survey_2014.pdf) (accessed Sep. 14, 
2020).
    \18\John H. Lacey et al., U.S. Department of Transportation, 
National Highway Traffic Safety Administration, Drug and Alcohol Crash 
Risk: A Case-Control Study, DOT HS 812 335, 
Dec. 2016, pp. 5-6 (https://www.nhtsa.gov/sites/nhtsa.dot.gov/files/
documents/812355_
drugalcoholcrashrisk.pdf) (accessed Sep. 14, 2020).
---------------------------------------------------------------------------

                         SUMMARY OF PROVISIONS

    S. 2979 would do the following:
   Make improvements in drug and alcohol testing for 
        employees in safety-sensitive transportation positions, 
        such as Amtrak locomotive engineers and conductors, 
        pipeline operators, and commercial motor vehicle 
        drivers.
   Initiate important research to combat drug-impaired 
        driving on our Nation's roads.

                          LEGISLATIVE HISTORY

    S. 2979 was introduced on December 4, 2019, by Senator 
Wicker and was referred to the Committee on Commerce, Science, 
and Transportation of the Senate. On December 11, 2019, the 
Committee met in open Executive Session and, by voice vote, 
ordered S. 2979 reported favorably with an amendment (in the 
nature of a substitute).
    During the 115th Congress, S. 2848, the Fighting Opioid 
Abuse in Transportation Act, was reported favorably with an 
amendment (in the nature of a substitute) by Senator Thune on 
behalf of the Committee on Commerce, Science, and 
Transportation of the Senate. That bill was enacted into law in 
subtitle I of the SUPPORT for Patients and Communities Act.\19\
---------------------------------------------------------------------------
    \19\Public Law 115-271.
---------------------------------------------------------------------------

                            ESTIMATED COSTS

    In accordance with paragraph 11(a) of rule XXVI of the 
Standing Rules of the Senate and section 403 of the 
Congressional Budget Act of 1974, the Committee provides the 
following cost estimate, prepared by the Congressional Budget 
Office:




    S. 2979 would require the Department of Transportation, the 
Department of Health and Human Services, and the Government 
Accountability Office to undertake several studies related to 
drug use and the prevention of such drug use by operators of 
different modes of transportation. Those agencies would be 
required to report to the Congress on the relevant findings at 
varying times following enactment.
    CBO assumes that the bill will be enacted in fiscal year 
2020. Under that assumption, the agencies could incur some 
costs in 2020, but CBO expects that most of the costs would be 
incurred in 2021 and later. Any spending would be subject to 
the availability of appropriated funds. Using information on 
the costs of similar studies and reports, CBO estimates that 
implementing S. 2979 would cost $2 million over the 2020-2025 
period.
    S. 2979 would impose a private-sector mandate as defined in 
the Unfunded Mandates Reform Act (UMRA) on the National 
Railroad Passenger Corporation (commonly known as Amtrak). The 
bill would require the company to establish an electronic 
database containing drug and alcohol test records for employees 
in safety-sensitive positions and establish procedures for 
tracking and monitoring drug and alcohol testing information 
maintained in the database. The bill would require Amtrak to 
complete those actions within 18 months of enactment and to 
submit two reports on related safety issues to the Congress.
    Because Amtrak already maintains the required information 
in paper form and the effort to comply with the reporting 
requirements would be small, CBO estimates the aggregate costs 
of the private-sector mandates would fall well below the annual 
threshold established in UMRA for private-sector mandates ($168 
million in 2020, adjusted annually for inflation).
    The bill also would require the Department of 
Transportation to consider whether existing regulations that 
apply to licensing locomotive engineers and conductors should 
include requirements to report drug- and alcohol-related 
arrests. If the department determines that the regulations 
should be modified, the bill would impose a private-sector 
mandate on locomotive engineers, conductors, and persons 
seeking certification to operate locomotives by requiring these 
individuals to report those offenses to Amtrak. Whether the 
department will issue a determination that the regulations 
should be modified is uncertain; however, fewer than 20,000 
Amtrak employees would be affected by the new reporting 
requirement. Therefore, CBO estimates the cost to comply with 
the mandate would be small.
    S. 2979 contains no intergovernmental mandates as defined 
in the UMRA.
    The CBO staff contacts for this estimate are Robert Reese 
(for federal costs) and Brandon Lever (for mandates). The 
estimate was reviewed by H. Samuel Papenfuss, Deputy Director 
of Budget Analysis.

                      REGULATORY IMPACT STATEMENT

    In accordance with paragraph 11(b) of rule XXVI of the 
Standing Rules of the Senate, the Committee provides the 
following evaluation of the regulatory impact of the 
legislation, as reported:

Number of Persons Covered

    S. 2979, as reported, would direct the Secretary of 
Transportation to determine whether regulations set forth in 
parts 240 and 242 of title 49, Code of Federal Regulations 
(CFR), should be revised to require locomotive engineers and 
conductors, or personnel seeking initial certification to 
become a locomotive engineer or a conductor, for Amtrak to 
report arrests due to drug or alcohol offenses as soon as 
practicable and before performing any safety-sensitive service 
as a locomotive engineer or conductor. Currently, regulations 
under 49 CFR 240.111(h) require certified locomotive engineers 
or persons seeking initial certification to report certain 
motor vehicle incidents within 48 hours of being convicted for, 
or completed State action to cancel, revoke, suspend, or deny a 
motor vehicle driver's license for, such violations. The same 
is required for certified conductors or persons seeking initial 
certification under 49 CFR 242.111(l). Depending on the 
Secretary of Transportation's determination as to whether the 
regulations in parts 240 and 242 of 49 CFR should be revised 
for locomotive engineers and conductors, or persons seeking 
initial certification to become a locomotive engineer or 
conductor, for Amtrak, S. 2979 could increase the number of 
persons covered for reporting arrests due to drug or alcohol 
offenses who are either locomotive engineers or conductors, or 
seeking to become locomotive engineers or conductors, for 
Amtrak.

Economic Impact

    S. 2979, as reported, is not expected to have an adverse 
impact on the Nation's economy.

Privacy

    S. 2979, as reported, does not raise any issues relating to 
privacy. Section 2 of S. 2979 would require Amtrak to establish 
an electronic database of all safety-sensitive positions to 
record data on employee drug and alcohol tests, but such data 
already is collected through paper records. The Committee 
recognizes potential risks associated with the electronic 
storage of this data, but believes Amtrak can take steps to 
ensure the security of the database.

Paperwork

    S. 2979, as reported, would increase certain paperwork 
requirements. Section 2 of the bill would require Amtrak to 
provide a report to Congress on methods used by Amtrak to 
ensure that supervisors of employees in safety-sensitive 
positions receive certain training and measures implemented to 
improve safety related to employee prescription drug use. This 
report would be a one-time submission with a limited scope.
    Section 4 of the bill would require DOT to submit a report 
to Congress on the ability of pipeline companies that operate 
from Canada or Mexico into the United States to conduct drug 
and alcohol testing and whether operators have sufficient 
testing in place to ensure safe operations. Section 6 of the 
bill would require NHTSA to study the ways in which the agency 
can reduce and better detect impaired driving, and section 7 of 
the bill would require DOT to study the accuracy of onsite 
fluid screening for tetrahydrocannabinol (i.e., THC) and opiate 
presence. Section 11 of the bill would require DOT to report on 
the status of the Driver Alcohol Detection System for Safety 
Program, and section 12 would require DOT, in consultation with 
other Federal agencies, to report to Congress on setting 
national minimum guidelines for toxicological investigations in 
cases of motor vehicle crashes and drug-impaired driving cases. 
These DOT studies and reports are important to ensuring the 
safety of our Nation's pipelines and combating impaired driving 
on our Nation's roads.
    Section 9 of the bill would require HHS to provide a status 
report on its determination of whether to add fentanyl to the 
drug testing panel, and section 10 would require the Office of 
Management and Budget (OMB) and HHS to provide status reports 
to Congress on hair testing guidelines as required by section 
5402(b) of the FAST Act.\20\ These two reporting requirements 
are expected to result in a small increase in paperwork for HHS 
and OMB.
---------------------------------------------------------------------------
    \20\49 U.S.C. 31306 note.
---------------------------------------------------------------------------

                   CONGRESSIONALLY DIRECTED SPENDING

    In compliance with paragraph 4(b) of rule XLIV of the 
Standing Rules of the Senate, the Committee provides that no 
provisions contained in the bill, as reported, meet the 
definition of congressionally directed spending items under the 
rule.

                      SECTION-BY-SECTION ANALYSIS

Section 1. Short title; table of contents.

    This section would provide that the bill may be cited as 
the ``Preventing Opioid and Drug Impairment in Transportation 
Act''. This section also provides a table of contents for the 
bill.

Section 2. Amtrak employee controlled substances and alcohol testing 
        records.

    This section would direct Amtrak to report to Congress, not 
later than 1 year after the date of enactment, on methods used 
to ensure supervisors of employees in safety-sensitive 
positions receive the required training on how to detect drug 
and alcohol use, as well as measures implemented to improve 
compliance with self-reporting of employee prescription drug 
use. Amtrak would also be required to establish an electronic 
database for employee drug and alcohol tests records, as well 
as effective procedures to track and monitor such testing, 
within 18 months after the date of enactment. Finally, Amtrak 
would be required to report to Congress on the measures 
implemented to improve safety related to employee prescription 
drug use, within 18 months after the date of enactment.

Section 3. Alcohol and controlled substance reporting of Amtrak 
        locomotive engineers and conductors.

    This section would direct DOT to make a determination, not 
later than 1 year after the date of enactment, as to whether 
existing regulations should be updated to require Amtrak 
locomotive engineers and conductors to report arrests due to 
drug or alcohol offenses as soon as practicable, and before any 
safety-sensitive service is performed. If the Secretary of 
Transportation determines that these regulations should be 
revised, the Secretary shall advise appropriate committees of 
jurisdiction of that determination and, not later than 18 
months after the determination, publish a proposed rule 
revision in the Federal Register that would require engineers 
and conductors (including those seeking initial certification) 
to report drug and alcohol offense arrests as soon as possible, 
define the scope of the reportable drug or alcohol offenses, 
and set the timeframe for which offenses are considered 
reportable prior to initial certification.

Section 4. Safety-sensitive personnel study.

    This section would require DOT to report to Congress, not 
later than 180 days after the date of enactment, on the ability 
of pipeline companies to require drug and alcohol testing of 
safety-sensitive personnel that are located outside of the 
United States but operate infrastructure within the United 
States, and indicate whether such operators have sufficient 
drug and alcohol testing procedures in place to ensure safe 
operations.

Section 5. Interstate drug and alcohol oversight.

    This section would require DOT to amend its pipeline 
auditing program, not later than 18 months after the date of 
enactment, to improve the efficiency of certain drug and 
alcohol regulations as applied to pipeline contractors working 
in multiple States or for multiple pipeline operators.

Section 6. Impaired driving study.

    This section would require NHTSA to report to Congress, not 
later than 2 years after the date of enactment, and biennially 
for the following 4 years, on the ways in which NHTSA can 
reduce and detect impaired driving, including marijuana- and 
opioid-impaired driving.

Section 7. Roadside oral fluid drug screening.

    This section would require DOT to study the accuracy of 
onsite oral fluid screening as a method to detect THC and 
opiate presence in drivers. Not later than 4 years after the 
date of enactment, the Secretary would be required to submit a 
report to Congress with the findings of the study and 
recommendations on the potential use of roadside oral fluid 
drug screening by law enforcement.

Section 8. GAO report on Department of Transportation drug testing 
        panel.

    This section would direct the U.S. Government 
Accountability Office (GAO) to review, not later than 2 years 
after the date of enactment, interactions between HHS and DOT 
in adding and removing categories of drugs from the testing 
panel and assess whether such process addresses the needs of 
the transportation industry for drug and alcohol testing to 
prevent drug and alcohol-related incidents.

Section 9. Transportation workplace drug and alcohol testing program; 
        status reports on addition of fentanyl.

    This section would amend the requirement established under 
section 8105 of subtitle I of the SUPPORT for Patients and 
Communities Act and require HHS to report to Congress, within 
30 days after the date of enactment, on the status of 
determining whether to add fentanyl to the drug panel.

Section 10. Status reports on scientific and technical guidelines for 
        hair testing of transportation employees.

    This section would require OMB, within 30 days after the 
date of enactment, and HHS, within 60 days after the date of 
enactment, to report to Congress on the status of the 
guidelines for hair testing to follow up on section 8106 of 
subtitle I of the SUPPORT for Patients and Communities Act. The 
Committee does not intend for this provision to change any of 
the requirements or considerations set forth in section 8106 of 
Public Law 115-271.

Section 11. Report on alcohol detection technology.

    This section would require DOT to submit a report to 
Congress, not later than 90 days after the date of enactment, 
that details the current status and operational potential of 
the Driver Alcohol Detection System for Safety Program's drunk-
driving detection technology.

Section 12. Report on collection of drug-impaired driving data.

    This section would require DOT, in consultation with 
appropriate Federal agencies, State highway safety offices, and 
other interested parties, to submit to Congress a report, not 
later than 3 years after the date of enactment, that identifies 
the barriers states face in submitting toxicology results of 
fatally injured drivers and provides recommendations to address 
those barriers and to establish minimum guidelines for 
toxicological investigations.

                        CHANGES IN EXISTING LAW

    In compliance with paragraph 12 of rule XXVI of the 
Standing Rules of the Senate, the Committee states that the 
bill as reported would make no change to existing law.